Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system

References

• Dong Z, Ye X, Chen C, et al. Thromboembolic events in Janus kinase inhibitors: apharmacovigilance study from 2012 to 2021 based on the food and drug administration’s adverse event reporting system. Br J Clin Pharmacol. 2022;88(9):4180–4190. DOI:10.1111/bcp.15361
   PubMed Web of Science ®Google Scholar
• Song Y, Song J, Kim K, et al. Potential adverse events reported with the janus kinase inhibitors approved for the treatment of rheumatoid arthritis using spontaneous reports and online patient reviews. Front Pharmacol. 2022;12:792877. DOI:10.3389/fphar.2021.792877
   PubMed Web of Science ®Google Scholar
• Shams S, M MJ, D DJR, et al. The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol. 2021;12:680043. DOI:10.3389/fphar.2021.680043
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Luo Y, J OJ, et al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133–145. DOI:10.1038/s41584-021-00726-8
   PubMed Web of Science ®Google Scholar
• Upadacitinib. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Aug 30, 2022.
   Google Scholar
• Singh JA. Treatment guidelines in rheumatoid arthritis. Rheum Dis Clin North Am. 2022;48(3):679–689. doi:10.1016/j.rdc.2022.03.005.
   PubMed Web of Science ®Google Scholar
• C S-FJ, Seija-Butnaru D, G VE, et al. Pain management strategies in rheumatoid arthritis: a narrative review. J Pain Palliat Care Pharmacother. 2021;35(4):291–299. DOI:10.1080/15360288.2021.1973647
   PubMed Web of Science ®Google Scholar
• Huang J, Fu X, Chen X, et al. Promising therapeutic targets for treatment of rheumatoid arthritis. Front Immunol. 2021;12:686155. DOI:10.3389/fimmu.2021.686155
   PubMed Web of Science ®Google Scholar
• Radu A, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10(11):2857. doi:10.3390/cells10112857.
   PubMed Web of Science ®Google Scholar
• Alves C, Penedones A, Mendes D, et al. The risk of infections associated with JAK inhibitors in rheumatoid arthritis. JCR: J Clinic Rheumatol. 2022;28(2):e407–e414. DOI:10.1097/RHU.0000000000001749
   PubMed Web of Science ®Google Scholar
• Fraenkel L, M BJ, R EB, et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumat. 2021;73(7):1108–1123. DOI:10.1002/art.41752
   PubMed Web of Science ®Google Scholar
• Rinvoq European Medicines Agency[EB/OL]. [2022/Dec/6]. https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq#authorisation-details-section.
   Google Scholar
• Duggan S, Keam SJ. Upadacitinib: first approval. Drugs. 2019;79(16):1819–1828. doi:10.1007/s40265-019-01211-z.
   PubMed Web of Science ®Google Scholar
• Boyce EG, Rogan ELC, Lui M. Upadacitinib for the treatment of rheumatoid arthritis: an extensive review. Ann Pharmacother. 2022;57(4):450–462. doi:10.1177/10600280221113092.
   PubMed Web of Science ®Google Scholar
• Muensterman E, Engelhardt B, Gopalakrishnan S, et al. Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials. Clin Transl Sci. 2022;15(1):267–278. DOI:10.1111/cts.13146
   PubMed Web of Science ®Google Scholar
• Drugs@FDA: FDA-Approved Drugs[EB/OL]. [2023/Mar/1]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process.
   Google Scholar
• D’Amico F, Peyrin-Biroulet L, Danese S. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(18):1767–1768 doi:10.1056/NEJMc2202778.
   PubMedGoogle Scholar
• Qian J, Xue X, Shannon J. Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration. J Manag Care Spec Pharm. 2022;28(9):1046–1052. doi:10.18553/jmcp.2022.28.9.1046.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Gori N, Narcisi A, et al. Effectiveness and safety of upadacitinib in the treatment of moderate-severe atopic dermatitis: a multicentric, prospective, real-world, cohort study. Drugs In R&D. 2022;22(3):245–252. DOI:10.1007/s40268-022-00396-1
   PubMed Web of Science ®Google Scholar
• Blauvelt A, D TH, L SE, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis. JAMA Dermatol. 2021;157(9):1047. DOI:10.1001/jamadermatol.2021.3023
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Mysler E, Bessette L, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open. 2022;8(1):e2012. DOI:10.1136/rmdopen-2021-002012
   PubMed Web of Science ®Google Scholar
• Cui C, Deng L, Wang W, et al. Respiratory system toxicity induced by immune checkpoint inhibitors: a real-world study based on the FDA adverse event reporting system database. Front Oncol. 2022;12:941079. DOI:10.3389/fonc.2022.941079
   PubMedGoogle Scholar
• Meudec L, Richebé P, Pascaud J, et al. Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity. Rheumatology. 2022; keac710. doi:10.1093/rheumatology/keac710
   PubMed Web of Science ®Google Scholar
• Shu Y, Ding Y, Dai B, et al. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opin Drug Saf. 2022;21(4):563–572. DOI:10.1080/14740338.2022.2016696
   PubMed Web of Science ®Google Scholar
• Shu Y, Ding Y, Liu Y, et al. Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol. 2022;13:862508. DOI:10.3389/fphar.2022.862508
   PubMed Web of Science ®Google Scholar
• Zhang P, Lao D, Chen H, et al. Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: an analysis of FAERS data in the past 15 years. Front Immunol. 2022;13:778635. DOI:10.3389/fimmu.2022.778635
   PubMedGoogle Scholar
• Shu Y, He X, Liu Y, et al. A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol. 2022;14:789–802. DOI:10.2147/CLEP.S365513
   PubMed Web of Science ®Google Scholar
• Guo M, Shu Y, Chen G, et al. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci Rep. 2022;12(1). doi:10.1038/s41598-022-23726-4
   Web of Science ®Google Scholar
• I VA, Alamanos Y, V VP, et al. Epidemiology of rheumatoid arthritis: genetic and environmental influences. Expert Rev Clin Immunol. 2022;18(9):923–931. DOI:10.1080/1744666X.2022.2106970
   PubMed Web of Science ®Google Scholar
• Drugs@FDA: FDA-Approved Drugs[EB/OL]. [2022/Sep/19]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearchprocess.
   Google Scholar
• Bretto E, D Amico F, Fiore W, et al. Lactobacillus paracasei CNCM I 1572: a promising candidate for management of colonic diverticular disease. J Clin Med. 2022;11(7):1916 doi:10.3390/jcm11071916.
   PubMed Web of Science ®Google Scholar
• Perez Hernandez C, Elkattawy S, Younes I, et al. A rare presentation of recurrent diverticulitis in a patient with ulcerative colitis. Eur j case rep int med. 2022;9(4):003271. doi: 10.12890/2022_003271
   PubMedGoogle Scholar
• Butter M, Weiler S, Biedermann L, et al. Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. Maturitas. 2018;110:71–78. DOI:10.1016/j.maturitas.2018.01.015
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113–2128. DOI:10.1016/S0140-6736(22)00581-5
   PubMed Web of Science ®Google Scholar
• Berthe P, Scailteux L, Lescoat A, et al. Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case–time control study and a nested case-control study based on the French national health insurance (SNDS) cohort. BMJ Open. 2022;12(9):e59979. DOI:10.1136/bmjopen-2021-059979
   Web of Science ®Google Scholar
• J SW, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139–2149. DOI:10.1053/j.gastro.2020.02.030
   PubMed Web of Science ®Google Scholar
• Yates M, Mootoo A, Adas M, et al. Venous thromboembolism risk with JAK inhibitors: a meta‐analysis. Arthritis & rheumat. 2021;73(5):779–788. DOI:10.1002/art.41580
   PubMed Web of Science ®Google Scholar
• Atzeni F, D PC, Nucera V, et al. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. Expert Rev Clin Immunol. 2022;18(3):233–244. DOI:10.1080/1744666X.2022.2039630
   PubMed Web of Science ®Google Scholar
• Zhao Y, Liu S, Li X, et al. Cross-talk of signaling pathways in the pathogenesis of allergic asthma and cataract. Protein Pept Lett. 2020;27(9):810–822. DOI:10.2174/0929866527666200207113439
   PubMed Web of Science ®Google Scholar
• Wang F, Sun L, Wang S, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(7):1404–1419. DOI:10.1016/j.mayocp.2020.01.039
   PubMed Web of Science ®Google Scholar
• B CS, van Vollenhoven RF, L WK, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheumatic Dis. 2021;80(3):304–311. DOI:10.1136/annrheumdis-2020-218510
   PubMed Web of Science ®Google Scholar
• Katoh N, Ohya Y, Murota H, et al. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): an interim 24-week analysis. JAAD Int. 2022;6:27–36. DOI:10.1016/j.jdin.2021.11.001
   PubMedGoogle Scholar
• B MI, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021;7(3):e1838. DOI:10.1136/rmdopen-2021-001838
   Web of Science ®Google Scholar
• E ON, Soliman A I F, Eshra M, et al. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS). ESMO Open. 2021;6(6):100315. DOI:10.1016/j.esmoop.2021.100315
   PubMed Web of Science ®Google Scholar
• Shu Y, Zhang Q, He X, et al. Fluoroquinolone-associated suspected tendonitis and tendon rupture: a pharmacovigilance analysis from 2016 to 2021 based on the FAERS database. Front Pharmacol. 2022;13:990241. DOI:10.3389/fphar.2022.990241
   PubMed Web of Science ®Google Scholar